Silverarc Capital Management LLC Purchases Shares of 183,243 Scholar Rock Holding Co. (NASDAQ:SRRK)

Silverarc Capital Management LLC acquired a new position in Scholar Rock Holding Co. (NASDAQ:SRRK) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 183,243 shares of the company’s stock, valued at approximately $7,920,000. Scholar Rock makes up 1.7% of Silverarc Capital Management LLC’s investment portfolio, making the stock its 19th biggest holding. Silverarc Capital Management LLC owned 0.20% of Scholar Rock at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SRRK. GAMMA Investing LLC lifted its holdings in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after acquiring an additional 269 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 766 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after buying an additional 620 shares during the period. Finally, KBC Group NV bought a new stake in shares of Scholar Rock in the 4th quarter valued at about $131,000. Institutional investors own 91.08% of the company’s stock.

Insider Transactions at Scholar Rock

In other news, insider Mo Qatanani sold 68,510 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares of the company’s stock, valued at $4,154,541.60. This represents a 38.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at approximately $2,373,490. This trade represents a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 250,231 shares of company stock valued at $9,056,086. Company insiders own 19.20% of the company’s stock.

Analyst Ratings Changes

Separately, Wedbush reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Scholar Rock has an average rating of “Buy” and a consensus target price of $42.67.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $29.81 on Tuesday. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a fifty day moving average of $33.11 and a 200 day moving average of $35.63. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -12.69 and a beta of 0.56. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $46.98.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.